Tempus to acquire Personalis for $1.5 billion

Tempus AI has agreed to acquire Personalis for $1.5 billion to expand its AI-powered cancer detection and precision oncology capabilities. This strategic acquisition targets a $20 billion market, specifically focusing on enhancing cancer MRD testing. By integrating Personalis, Tempus AI aims to leverage AI-driven precision oncology to improve diagnostic accuracy. The deal represents a significant investment in the oncology sector, utilizing advanced technology to scale its reach within the molecular residual disease testing landscape.